Mercer Global Advisors Inc. ADV Buys New Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Mercer Global Advisors Inc. ADV bought a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,836 shares of the company’s stock, valued at approximately $116,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DNA. Forbes J M & Co. LLP grew its position in Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock valued at $6,891,000 after buying an additional 576,732 shares in the last quarter. Erste Asset Management GmbH boosted its position in shares of Ginkgo Bioworks by 47.9% during the 4th quarter. Erste Asset Management GmbH now owns 739,332 shares of the company’s stock valued at $6,979,000 after purchasing an additional 239,332 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Ginkgo Bioworks during the 4th quarter valued at about $1,796,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Ginkgo Bioworks during the 4th quarter valued at about $1,000,000. Finally, Prescott Group Capital Management L.L.C. boosted its position in shares of Ginkgo Bioworks by 33.1% during the 4th quarter. Prescott Group Capital Management L.L.C. now owns 361,750 shares of the company’s stock valued at $3,552,000 after purchasing an additional 90,000 shares in the last quarter. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Trading Up 3.3%

NYSE:DNA opened at $7.92 on Friday. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $33.20. The company has a 50-day moving average of $7.17 and a 200-day moving average of $9.07. The firm has a market cap of $459.75 million, a price-to-earnings ratio of -0.61 and a beta of 1.29.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The business had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. On average, research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.